Email this article 
New opportunities of therapy of severe atopic dermatitis
- Authors: Demko I.v1,2, Sobko E.A.1,2, Kraposhina A.Y.1,2, Shestakova N.A.1,2, Gordeeva N.V.1,2, Kasymova K.F.1
-
Affiliations:
- Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
- Krasnoyarsk Clinical Regional Hospital
- Issue: Vol 18, No 3 (2021)
- Pages: 113-119
- Section: Case reports
- URL: https://rusalljournal.ru/raj/article/view/1465
- DOI: https://doi.org/10.36691/RJA1465
Cite item
Open Access
Access granted
Abstract
This article presents a case of the successful use of dupilumab in a 21-year-old patient with severe atopic dermatitis, concomitant bronchial asthma, and allergic rhinitis. The patient was observed in the allergological department of the Krasnoyarsk Clinical Regional Hospital for 2 years. The disease was characterized by constant skin symptoms, frequent exacerbations, resistance to standard therapy, including systemic glucocorticosteroids and immunosuppressors. Considering the above factors, targeted therapy was started with dupilumab, registered in the Russian Federation for use in atopic dermatitis resistant to standard therapy. Against the background of biological therapy (13 injections were carried out), a stable significant decrease in skin syndrome activity was achieved (SCORAD index decreased from 72 to 9 points), and the patient’s quality of life significantly improved.
Keywords
Full Text
About the authors
Irina v Demko
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital
Email: demko64@mail.ru
ORCID iD: 0000-0001-8982-5292
SPIN-code: 6520-3233
MD, Dr. Sci. (Med.), Professor
Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; KrasnoyarskElena A. Sobko
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital
Email: sobko29@mail.ru
ORCID iD: 0000-0002-9377-5213
SPIN-code: 9132-6756
MD, Dr. Sci. (Med.), Professor
Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; KrasnoyarskAngelina Yu. Kraposhina
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital
Author for correspondence.
Email: angelina-maria@inbox.ru
ORCID iD: 0000-0001-6896-877X
SPIN-code: 8829-9240
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; KrasnoyarskNatalia A. Shestakova
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital
Email: barsk@rambler.ru
ORCID iD: 0000-0002-2252-7423
SPIN-code: 4579-4502
MD, Cand. Sci. (Med.)
Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; KrasnoyarskNatalia V. Gordeeva
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Clinical Regional Hospital
Email: natagorday@yandex.ru
ORCID iD: 0000-0002-0586-8349
SPIN-code: 7914-7630
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022; KrasnoyarskKarina F. Kasymova
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Email: ayaneshiroi@gmail.com
ORCID iD: 0000-0001-8448-6113
SPIN-code: 4691-2399
MD
Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022References
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
- Kozyeva VV. Prevalence of bronchial asthma and atopic dermatitis in children. Allea nauki. 2017;3(9):469–472. (In Russ).
- Dyneva ME, Aminova GE, Kurbacheva OM, et al. Dupilumab: new opportunities for the treatment of asthma and chronic rhinosinusitis with nasal polyps. Russian Journal of Allergy. 2021;18(1):18–31. (In Russ). doi: 10.36691/RJA1408
- Smolkin YS, Balabolkin II, Gorlanov IA, et al. Consensus document APAIR: atopic dermatitis in children — update 2019 (short version). Part 1. Allergol Immunol Pediatr. 2020;60(1):4–25. doi: 10.24411/2500-1175-2020-10001
- Snast I, Reer O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145–165. doi: 10.1007/s40257-017-0324-7
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1
- Thaçi D, Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. doi: 10.1016/j.jdermsci.2019.02.002
- Lowe AJ, Leung DY, Tang ML, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151. doi: 10.1016/j.anai.2017.11.023
- Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):209–213. doi: 10.1016/j.jaci.2006.04.043
- Smolkin YS, Masalsky SS, Smolkina OY. The application of the biological treatment in atopic dermatitis: focus on dupilumab. Allergology and Immunology in Pediatrics. 2020;61(2):27–40. (In Russ). doi: 10.24411/2500-1175-2020-10005
- Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019;56(10):1110–1119. doi: 10.1080/02770903.2018.1520865
- Tozawa H, Kanki Y, Suehiro J, et al. Genome-wide approaches reveal functional interleukin-4-inducible STAT6 binding to the vascular cell adhesion molecule 1 promoter. Mol Cell Biol 2011;31(11):2196–2209. doi: 10.1128/MCB.01430-10
- Mineev VN, Sorokina LN, Trofimov VI, et al. Interleukin-4 and interleukin-13 receptors: structure, function and genetic polymorphism. Pulmonology. 2010;(3):113–119. (In Russ).
- Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–69. doi: 10.1016/j.jaad.2017.09.052
- Balabolkin II, Terletskaya RN, Modestov AA. Allergic morbidity of children in modern environmental conditions. Siberian Medical Review. 2015;91(1):63–67. (In Russ).
Supplementary files
